The PIVENS trial demonstrated that pioglitazone treatment significantly reduced steatosis and inflammatory features such as hepatocellular ballooning in non-alcoholic steatohepatitis (NASH) patients.8 PPARγ agonists have also been shown to decrease inflammation and tumorigenesis in multiple tumor models, such as colon, thyroid and lung cancers.9 Here, PPARG is linked to metabolic dysfunction-associated steatohepatitis.